AARD insider buying – Aardvark Therapeutics, Inc.
9 insider purchases since 2016 worth $23.9M by 4 different insiders. Last 12 months: 2 purchases, $144,630. Most recent filing: 2025-12-12.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. 10% Owner | $20.0M 1× · 1,250,000 sh | 2025-02-14 2025-02-14 | – | 3,292,299 shares as of 2025-02-19 | Holds - never sold |
| Chen Bihua Other | $3.0M 1× · 187,500 sh | 2025-02-14 2025-02-14 | – | 800,189 shares as of 2025-02-19 | Holds - never sold |
| Lee Tien-Li CEO | $623,317 4× · 53,542 sh | 2025-02-14 2025-12-11 | – | 3,025,641 shares as of 2025-12-12 | Holds - never sold |
| Sun Nelson CFO | $251,620 3× · 19,000 sh | 2025-02-14 2025-12-11 | 1× · $394,930 last 2026-09-10 | 97,475 shares as of 2026-09-11 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 1 | $394,930 |
| 2025 | 9 | $23.9M | 4 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | Sun Nelson | CFO | 3,000 | $14.40 | $43,200 | +2.8% | SEC |
| 2025-12-12 | Lee Tien-Li | CEO | 7,000 | $14.49 | $101,430 | +0.5% | SEC |
| 2025-09-16 | Lee Tien-Li | CEO | 10,000 | $9.66 | $96,605 | +0.7% | SEC |
| 2025-09-12 | Lee Tien-Li | CEO | 20,000 | $8.03 | $160,610 | +1.3% | SEC |
| 2025-09-10 | Sun Nelson | CFO | 6,000 | $8.07 | $48,420 | +6.0% | SEC |
| 2025-02-19 | Sun Nelson | CFO | 10,000 | $16.00 | $160,000 | +11.2% | SEC |
| 2025-02-19 | Lee Tien-Li | CEO | 16,542 | $16.00 | $264,672 | +1.1% | SEC |
| 2025-02-19 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | 1,250,000 | $16.00 | $20.0M | +73.1% | SEC |
| 2025-02-19 | Chen Bihua | Other | 187,500 | $16.00 | $3.0M | +23.4% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sun Nelson | Officer | 76,754 | $5.15 | $394,930 | Sale | SEC |
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free